There are quite a few people who contribute to science that we may not hear about as much for one reason or other. But they help to advance science, improve lives, and immense value in more ways than one. The current state of the world is uncertainty due to the current pandemic. But thankfully, there are scientists like Ian MacLachlan who are able to use their skills, knowledge, and overall energy to help solve problems.
Here is what you need to know about Ian MacLachlan and his contributions to science and the world at the present moment.
Ian MacLachlan and Pfizer-BioNTech
The Pfizer-BioNTech vaccine got created using messenger RNA technology, which directs the body’s immune system on how to battle the coronavirus. However, the mRNA had to get wrapped in lipids to enter human cells safely.
Ian MacLachlan, a little-known 57-year-old Canadian biochemist, is mainly responsible for this critical delivery method and is the chief scientific officer of two small companies, Protiva Biotherapeutics and Tekmira Pharmaceuticals.
This small but crucial discovery helped to pave the way for the creation and distribution of these forms of therapy.
These Firms Will Invest Much More to Obtain Rewards Due to the Work of People like Ian MacLachlan
Moderna, BioNTech, and Pfizer are on track to sell $45 billion in vaccines by 2021. Yet, they don’t pay MacLachlan a cent. Despite their claims, research journals and legislative records submitted with the FDA reveal how both Moderna and Pfizer-vaccines BioNTech employ a delivery method identical to the one developed by MacLachlan and his colleagues.
It all started with the competition between these two scientists, MacLachlan and Madden. They have a complex history, but this history led to the discovery of the binding lipid, a big part of the vaccines we use today. Unfortunately, their bitter entanglements caused a slew of legal battles, all to protect their discoveries.
The litigation gave Madden’s company access to produce MacLachlan delivery method to build new mRNA products from scratch. By this point, Moderna CEO Stéphane Bancel had teamed up with Madden to address the delivery problem.
Moderna soon tried to get the patent in their wing when Madden lost the rights to it. Thomas Madden then collaborated on the Pfizer-BioNTech vaccine delivery system, and both claim to have employed improved versions of two of the four lipid types.
Unfortunately, the Biden Administration supported removing intellectual property protection for Covid-19 vaccinations in May. But, in an ironic twist, such a move may assist rather than harm Moderna, BioNTech, and Pfizer.